NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi Pasteur, a Sanofi Company
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Countries: South Korea
The purpose of the study is to perform the re-examination of Menactra® administered in the routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation. Primary objective: * To describe the safety profile after 1 dose of Menactra® administered from 9 months to 55 years of age under standard health care practice.
Sex: ALL
Age: 9 Months to 55 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Informed consent form signed by the subject (for subjects from 19 to 55 years of age) or the parent(s) or other legal representative (for subjects from 9 months to 18 years of age) * Receipt of one dose of Menactra® (on the day of inclusion) according to approved local product insert paper . Exclusion Criteria: * Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or a medical procedure * Subjects who already participated in this study.
- Seoul, South Korea